2 terminated, 2 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Unknown 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Attenuon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ATN-224 in Patients With Prostate Cancer ATN-224 - Prostate Cancer | Phase 2 | Unknown | Attenuon | 50 | 2006-11-01 | 2008-01-30 |
| Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma ATN-224, Temozolomide - Melanoma | Phase 2 | Unknown | Attenuon | 60 | 2006-09-01 | 2007-12-06 |
| A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma ATN-224 + bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Attenuon | 46 | 2006-06-01 | 2008-10-28 |
| ATN-161 in Advanced Renal Cell Cancer ATN-161 - Carcinoma, Renal Cell | Phase 2 | Terminated | Attenuon | 36 | 2005-08-01 | 2007-12-06 |
Recurrence (2) · Carcinoma, Renal Cell (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1)
tetrathiomolybdate (3) · Bortezomib (1) · Temozolomide (1) · acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide (1)
United States (4)
Gilad Gordon, MD (3)